NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,826 | -28.5% | 9,011 | -9.1% | 0.04% | -27.1% |
| Q2 2023 | $99,021 | +36.3% | 9,912 | +21.2% | 0.06% | +47.5% |
| Q1 2023 | $72,647 | -41.6% | 8,181 | -27.8% | 0.04% | -38.5% |
| Q4 2022 | $124,425 | -11.8% | 11,332 | +4.8% | 0.06% | +16.1% |
| Q3 2022 | $141,000 | +3.7% | 10,813 | +0.7% | 0.06% | +12.0% |
| Q2 2022 | $136,000 | +70.0% | 10,735 | +89.1% | 0.05% | +38.9% |
| Q1 2022 | $80,000 | -54.0% | 5,676 | -5.6% | 0.04% | -45.5% |
| Q4 2021 | $174,000 | -19.4% | 6,010 | -16.4% | 0.07% | -30.5% |
| Q3 2021 | $216,000 | +7.5% | 7,193 | -5.0% | 0.10% | +14.5% |
| Q2 2021 | $201,000 | – | 7,570 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |